Bridget A. Ross Sells 3,750 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded up $0.19 during midday trading on Tuesday, hitting $103.74. 81,831 shares of the company’s stock traded hands, compared to its average volume of 124,101. LeMaitre Vascular, Inc. has a twelve month low of $51.70 and a twelve month high of $106.49. The firm’s fifty day moving average price is $92.45 and its two-hundred day moving average price is $86.15. The company has a market cap of $2.33 billion, a PE ratio of 56.69, a P/E/G ratio of 2.50 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period in the previous year, the company posted $0.33 EPS. LeMaitre Vascular’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors have recently added to or reduced their stakes in LMAT. Glenmede Trust Co. NA increased its position in shares of LeMaitre Vascular by 1.3% during the third quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock worth $976,000 after acquiring an additional 136 shares during the last quarter. Summit Global Investments increased its holdings in LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock worth $575,000 after purchasing an additional 146 shares during the last quarter. Shaker Investments LLC OH raised its position in shares of LeMaitre Vascular by 1.3% in the 2nd quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after purchasing an additional 175 shares in the last quarter. NBC Securities Inc. boosted its stake in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 188 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of recent analyst reports. Barrington Research lifted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. JMP Securities upped their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Finally, Oppenheimer reissued an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.